Showing results (501-510 of 525) with videos related to

Sort By:
Pageof 53
Immunity|January 15, 2013
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua-Xin Liao, Mattia Bonsignori, S Munir Alam, et al.
Science Immunology|August 8, 2017
Potent and broad HIV-neutralizing antibodies in memory B cells and plasmaLaTonya D Williams, Gilad Ofek, Sebastian Schätzle, et al.
Nature Medicine|August 22, 2022
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisitionPeter B Gilbert, Yunda Huang, Allan C deCamp, et al.
Ebiomedicine|June 10, 2023
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionKelly E Seaton, Yunda Huang, Shelly Karuna, et al.
The Journal of Infectious Diseases|June 27, 2022
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition RiskZoe Moodie, One Dintwe, Sheetal Sawant, et al.
Plos Pathogens|August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Journal of Virology|November 10, 2025
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivityParker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, et al.
The Lancet. HIV|May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trialSharana Mahomed, Carmen A Paez, Yunda Huang, et al.
Science Immunology|July 16, 2021
A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primatesMaria Pino, Talha Abid, Susan Pereira Ribeiro, et al.
Pageof 53